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Abstract 
Alzheimer's disease (AD) is the most common cause of dementia. It is the fifth-leading cause of death among 
elderly people. With high genetic heritability (79%), finding disease causal genes is a crucial step in find 
treatment for AD. Following the International Genomics of Alzheimer’s Project (IGAP), many disease-
associated genes have been identified; however, we don't have enough knowledge about how those disease-
associated genes affect gene expression and disease-related pathways. We integrated GWAS summary data 
from IGAP and five different expression level data by using TWAS method and identified 15 disease causal 
genes under strict multiple testing (alpha < 0.05), 4 genes are newly identified; identified additional 29 potential 
disease causal genes under false discovery rate (alpha < 0.05), 21 of them are newly identified. Many genes we 
identified are also associated with some autoimmune disorder. 
Key Words: Alzheimer’s disease, genome-wide association study, autoimmune diseases, transcriptome-wide 
association study, false discover rate.  
 
                                                     
1  
Introduction 
Alzheimer's disease is the most common cause of dementia which is characterized by a decline in cognitive skills that 
affects a person's ability to perform everyday activities. Estimated 5.4 million people in the U.S. are living with 
Alzheimer's disease (AD). It is the fifth-leading cause of death among those age 65 and older[1]. Although some drugs 
showing effectiveness to mitigate the symptoms from getting worse for a limit time, no treatment can stop the disease.  
Heritability for the AD was estimated up to 79% [2]. However, the current finding of AD-associated genetic variants is 
not enough to fully explain the AD signal pathway in sufficient detail. 
During recent years, with the rapid advance of next-generation DNA sequencing, identify disease-related mutation from 
large data set and develop treatment become possible [3-5]. Genome-wide comparison studies (GWAS) have identified a 
significant amount of common genetic variants associated with complex traits and diseases [6-8]. Many previous studies 
have identified genes such as APOE[9, 10] on chromosome 19. However, the causal relation of those associated genes and 
variants remain unclear. For example, recent study and data showed that a female with the APOE gene under greater risk 
than a male with the APOE gene[11, 12].  This strongly indicates that we have little knowledge about how this risk factor 
effect people.  
With GWAS summary data provided by the International Genomics of Alzheimer's Project (IGAP) [13], we are able to 
study AD in great detail. For a complex disease such as AD, the top  single nucleotide polymorphisms (SNPs) often 
located in the noncoding region, hard to know which gene is modified by that mutation and many significant SNPs are in 
high linkage disequilibrium with non-significant SNPs,  plus many associated SNPs  are more likely to locate in 
expression regulation region of the disease causal gene[14, 15].  To identify disease-associated genes, we used the 
transcriptome-wide association study (TWAS) [16] method which integrates GWAS summarization level data, 
expression level data from human tissue. TWAS method can eliminate potential confounding and find disease 
causal gene by focusing only on expression trait linking related by genetic variation; it can also increase 
statistical power from the lower multiple-testing burden and the noise reduction of gene expression from 
environmental factors[16].  
Previous studies have pointed out at AD is closely related to autoimmune disorders. [17, 18]. After detecting 
possible disease causal gene for AD, we manually curated existing research about the autoimmune diseases that 
potentially related to AD. 
 
Data and Method 
Data we used for SNP-trait association is a large-scale GWAS summary data provided by IGAP with total 17,008 AD 
cases and 37,154 controls, include 7,055,881 SNPs, we selected 6,004,159 SNPs. Expression level data are from adipose 
tissue (RNA-seq), whole blood (RNA array), peripheral blood (RNA array), brain tissue (RNA-seq and RNA-seq 
splicing) [19-22].  
Transcriptome-wide Association Study 
TWAS can be viewed as a test for correlation between predicted gene expression and traits from GWAS summary 
association data. The predicted effect size of gene expression on traits can be viewed as a linear model of genotypes with 
weights based on the correlation between SNPs and gene expression in the training data while accounting for linkage 
disequilibrium (LD) among SNPs.   
There are eight modes of causality for the relationship between genetic variant, gene expression, and traits. Scenarios E-H 
in Figure-1 should be identified as significant by TWAS and its corresponding null hypothesis is gene expression 
completely independent of traits (A-D in Figure 1). By only focusing on the genetic component of expression, the 
instances of expression-trait association that is not caused by genetic variation but variation in traits can be avoided. One 
aspect that needs to be noticed is, same as other methods, TWAS is also confounded by linkage and pleiotropy. 
 
Figure-1 
Eight scenarios of causal assumption between gene, expression and trait in TWAS study. Null hypothesis: gene 
expression is completely independent of traits(A-D) Alternative hypothesis: causal relation exists between SNPs and 
traits(E-H) 
 
Performing TWAS with GWAS Summary Statistics  
We integrated gene expression measurements from 5 tissues with summary GWAS to perform multi-tissue transcriptome-
wide association. In each tissue, TWAS used cross-validation to compare predictions from the best cis-eQTL to those 
from all SNPs at the locus. Prediction models choosing from BLUP, BSLLM [23], LASSO, and elastic net [24].  
TWAS Imputes effect size (𝑧-score) of the expression and trait are linear combination of elements of 𝑧-score of SNPs for 
traits with weights. The weights, 𝑊 = 𝛴𝑒,𝑠𝛴𝑠,𝑠
−1, are calculated using ImpG-Summary algorithm[25] and adjusted for 
Linkage Disequilibrium(LD) . 𝛴𝑒,𝑠 is the estimated covariance matrix between all SNPs at the locus and gene expression 
and 𝛴𝑠,𝑠  is the estimated covariance among all SNPs which is used to account for LD.  
Standardized effect sizes (Z-scores) of SNPs for a trait at a given cis locus can be denoted as a vector 𝑍. Also, the imputed 
Z-score of expression and trait, 𝑊𝑍, has variance. 𝑊𝛴𝑠,𝑠𝑊
𝑡. Therefore, the imputation Z score of the cis genetic effect on 
the trait is, 
ZTWAS = WZ/(WΣs,sW
t)1/2. 
 
Bonferroni correction is usually applied when identifying significant disease-associated gene. The standard multiple 
testing conducted in TWAS is 0.05/15000 [16]. But traditional P-value cutoffs adjusted by Bonferroni correction are made 
too strict in order to avoid an abundance of false positive results. The thresholds like 0.05/15000 for significant genes are 
usually chosen so that the probability of any single false positive among all loci tested is smaller than 0.05, which will 
lead to many missed findings. Instead, False Discovery Rate error measure is a more useful approach when a study 
involves a large number of tests, since it can identify as many significant genes as possible while incurring a relatively 
low proportion of false positives.[26] For each tissue, we used the Benjamini-Hochberg procedure [27] in addition to the 
Bonferroni correction for all gene tested. The Benjamini-Hochberg procedure is one of false discovery rate procedures 
that are designed to control the expected proportion of false positives. It is less stringent than the Bonferroni correction, 
thus has greater power. Since this is study is more exploratory, we can pay more risk of type I error for larger statistical 
power. It works as follows: 
Put individual p-values in ascending order and assign ranks to the p-values. 
1. Calculate each individual Benjamini-Hochberg critical value with formula 
𝑘
𝑚
𝛼, where 𝑘 is individual p-value’s rank, 
𝑚 is total number of tests and 𝛼 is the false discovery rate. 
2. Find the largest 𝑘 such that 𝑃𝑘 ≤
𝑘
𝑚
𝛼 and reject the null hypothesis for all 𝐻𝑖 for 𝑖 = 1, … 𝑘. 
 
Results  
To determine which gene is significantly associated with AD, we first performed strict multiple testing Bonferroni 
correction (P-value < 0.05/15000). (Sample results see Figure-2) We found 15 significant genes (Table-1), 11 of them has 
identified by previous studies of AD.  In order to increase the search range, we performed false discovery rate under the 
same alpha (0.05). After the Benjamini-Hochberg procedure [27], we found 29 additional genes (Table-2). Nine of those 
genes has previously identified to be related to AD. 
PVRL2(P-value 4.92*10^-34 in Brain (CMC) RNA-seq, also known as NECTIN2) is a well-known gene for AD. This 
gene encodes a single-pass type I membrane glycoprotein and interact with AOPE gene [28]. TOMM40 (P-value 
1.13*10^-25 in Whole Blood (YFS) RNA Array) is also located adjacent to APOE. It has been identified by previous 
studies worldwide as AD related gene [29-31]. It is the central and essential component of the translocase of the outer 
mitochondrial membrane[32]. This confirmed that mitochondrial dysfunction plays a significant role in AD-related 
pathology[33, 34] 
Other highly connected genes function group identified are BIN1(P-value 1.18 × 10−6in Whole Blood (YFS) RNA 
Array; 3.24 × 10−6in Peripheral Blood(NTR) RNA Array), CLU(P-value1.45 × 10−16, MS4A6A(P-value 5.72 ×
10−8in Peripheral Blood(NTR) RNA Array; 2.92 × 10−10in Whole Blood (YFS) RNA Array)[35].  
 
. 
Figure-2 
Gene position plot in chromosome 19.  
New Identified Genes 
MLH3(P-value 7.86 × 10−9 in Brain (CMC) RNA-seq splicing) FNBP4(P-value 1.49 × 10−6in Whole Blood (YFS) 
RNA Array, CEACAM19(P-value 3.38 × 10−11 in Adipose (METSIM) RNA-seq), and CLPTM1(P-value 5.73 × 10−17 
in Brain (CMC) RNA-seq) are newly identified AD-associated genes. MLH3 gene is known for its function in repair 
mismatched DNA and risk for thyroid cancer and lupus[36-38]. CEACAM19 gene located in chromosome 19, a previous 
study showed high expression of CEACAM19 for patients with breast cancer[39]; CLPTM1 has been shown to increase 
the risk of lung cancer and melanoma [40, 41]. Both CEACAM19 and CLPTM1 gene are located in chromosome 19 and 
near APOE gene. More detailed studies are needed to investigate the relationship between those genes and whether 
CLPTM1 and CEACAM19 are disease causal gene. 
 
Discussion 
APOE Related Genes 
Although APOE is not reported to be significant in any tissue, not enough evidence to conclude that APOE is not related 
to AD. Since each SNP has a weight assigned regarding the expression in TWAS study, even two genes are both 
significantly related to a disease, it is very likely only one of them will be showing significant in TWAS. TOMM40(P-
value 1.13 × 10−25) gene located adjacent to APOE[42], and has a strong linkage disequilibrium with APOE gene[43], 
hence TWAS didn't detect this APOE does not imply it is not disease causal gene.  APOE and TOMM40 may interact to 
affect AD pathology such as mitochondrial dysfunction [44, 45]. Further study is needed to show causal relation in detail. 
PICALM (P-value 2084 × 10−7 in Peripheral Blood (NTR) RNA Array) and PTK2B(P-value 9.93 × 10−8 in Peripheral 
Blood (NTR) RNA Array; P-value 2.89 × 10−6 in Whole Blood (YFS) RNA Array) are also related to APOE and 
TOMM40 gene according to previous studies [35, 46-48].  
Association with Autoimmune Diseases 
Complex disease such as AD, often shares common pathways or causal genes with other diseases.[49]  For instance, 
TOMM40 is a shared disease-associated gene between AD and Type II diabetes[50]. Recent studies showing autoimmune 
diseases have closed relation with AD [51-53]. Among all the genes we identified through TWAS method, eight of them 
are related to autoimmune diseases.  
As shown in Figure-3, PICALM, PVRL2, PVR, and CLU have shown to be related to systemic, an autoimmune disease 
characterized by vascular injury and debilitating tissue fibrosis [54-57]. CR1 and CLU gene are related to thymus function 
which could potentially cause an autoimmune disorder [58, 59]. MLH3 and BIN1 gene have shown to be associated with 
Lupus, another severe autoimmune disease [37, 60]. Although with existing result, we don't have enough evidence to 
prove these genes are both disease causal genes for AD and autoimmune disease, further research from areas such as 
metabolomics and proteomics is needed to study the disease association between AD and autoimmune diseases [61-63]. 
 
Figure-3 
Shared disease associated gene between Alzheimer’s disease and Autoimmune diseases 
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Appendix 
Table1: Significant genes identified by TWAS under strict multiple testing 
 
 
 
 
Tabel2:Additional gene under Benjamini-Hochberg procedure 
Gene Chromosome Tissue P-value Z-score Previously  
Identified 
Gene  Chromosome Tissue P-value Z-score Related to 
Autoimmune 
Diseases 
PVRL2 19 Brain (CMC) RNA-seq 4.92E-
34 
-12.1626  Yes 
TOMM40 19 Whole Blood (YFS) RNA 
Arr 
 
ay 
1.13E-
25 
10.4749   
CLPTM1 19 Brain (CMC) RNA-seq 5.73E-
17 
-8.37061   
CLU 8 Brain (CMC) RNA-seq 
splicing 
1.45E-
16 
-8.26075   
CR1 1 Brain (CMC) RNA-seq 4.08E-
15 
7.8523  Yes 
CEACAM19 19 Adipose (METSIM) RNA-
seq 
3.38E-
11 
6.62905  Yes 
MS4A6A 11 Whole Blood (YFS) RNA 
Array 
2.92E-
10 
6.30316   
TRPC4AP 20 Brain (CMC) RNA-seq 
splicing 
9.43E-
10 
6.1188   
MLH3 14 Brain (CMC) RNA-seq 
splicing 
7.86E-
09 
-5.77148  Yes 
MS4A6A 11 Peripheral Blood (NTR) 
RNA Array 
5.72E-
08 
5.4272   
PTK2B 8 Peripheral Blood (NTR) 
RNA Array 
9.93E-
08 
5.32809   
PVR 19 Brain (CMC) RNA-seq 2.05E-
07 
-5.19443  Yes 
PICALM 11 Peripheral Blood (NTR) 
RNA Array 
2.84E-
07 
5.1337  Yes 
MS4A4A 11 Adipose (METSIM) RNA-
seq 
6.11E-
07 
4.99   
BIN1 2 Whole Blood (YFS) RNA 
Array 
1.18E-
06 
4.859114   
FNBP4 11 Whole Blood (YFS) RNA 
Array 
1.49E-
06 
-4.81307   
PTK2B 8 Whole Blood (YFS) RNA 
Array 
2.89E-
06 
4.6784  Yes 
BIN1 2 Peripheral Blood (NTR) 
RNA Array 
3.24E-
06 
4.65503 Yes 
PHACTR1 6 Whole Blood (YFS) RNA Array 3.41E-06 -4.64434   
PTPMT1 11 Whole Blood (YFS) RNA Array 4.45E-06 4.58895   
MTCH2 11 Peripheral Blood (NTR) RNA 
Array 
5.76E-06 4.535   
C1QTNF4 11 Adipose (METSIM) RNA-seq 8.82E-06 4.44   
FAM180B 11 Brain (CMC) RNA-seq 1.09E-05 -4.39814  Yes 
DMWD 19 Whole Blood (YFS) RNA Array 1.22E-05 4.3733   
ELL 19 Whole Blood (YFS) RNA Array 1.89E-05 4.277  Yes 
ZNF740 12 Brain (CMC) RNA-seq splicing 2.08E-05 4.25599   
NYAP1 7 Adipose (METSIM) RNA-seq 2.47E-05 -4.21777   
SDAD1 4 Whole Blood (YFS) RNA Array 3.04E-05 -4.17062   
MTSS1L 16 Brain (CMC) RNA-seq splicing 3.35E-05 4.14833   
PHKB 16 Brain (CMC) RNA-seq 3.70E-05 -4.1257  Yes 
SLC39A13 11 Brain (CMC) RNA-seq splicing 4.01E-05 -4.10667  Yes 
CD33 19 Whole Blood (YFS) RNA Array 4.04E-05 4.1051  Yes 
AP2A2 11 Brain (CMC) RNA-seq 4.28E-05 -4.09193  Yes 
ZYX 7 Adipose (METSIM) RNA-seq 4.56E-05 -4.07718   
ZNF232 17 Brain (CMC) RNA-seq splicing 4.73E-05 -4.0688   
ZNF232 17 Brain (CMC) RNA-seq splicing 4.76E-05 4.0671   
DLST 14 Peripheral Blood (NTR) RNA 
Array 
5.26E-05 4.0436  Yes 
TBC1D7 6 Adipose (METSIM) RNA-seq 5.34E-05 4.0403   
ELL 19 Adipose (METSIM) RNA-seq 5.48E-05 4.03401   
SLC39A13 11 Brain (CMC) RNA-seq splicing 5.79E-05 -4.02128  Yes 
TMCO6 5 Whole Blood (YFS) RNA Array 6.50E-05 3.9938   
CEL 9 Whole Blood (YFS) RNA Array 6.99E-05 3.97671  Yes 
MYBPC3 11 Adipose (METSIM) RNA-seq 7.05E-05 3.97  Yes 
TBC1D7 6 Brain (CMC) RNA-seq splicing 7.48E-05 -3.96063   
LRRC25 19 Peripheral Blood (NTR) RNA 
Array 
7.74E-05 -3.9523   
TBC1D7 6 Brain (CMC) RNA-seq splicing 8.37E-05 3.93351   
KIR3DX1 19 Peripheral Blood (NTR) RNA 
Array 
8.87E-05 3.9195   
SIX5 19 Peripheral Blood (NTR) RNA 
Array 
9.32E-05 3.9076   
HBEGF 5 Whole Blood (YFS) RNA Array 9.92E-05 -3.8926  Yes 
NUP88 17 Peripheral Blood (NTR) RNA 
Array 
1.60E-04 -3.7748   
FAM105B 5 Whole Blood (YFS) RNA Array 1.61E-04 3.773   
ARL6IP4 12 Peripheral Blood (NTR) RNA 
Array 
2.10E-04 3.707   
 
 
